Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.
about
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?The specialist physician's approach to rheumatoid arthritis in South AfricaTreatment of rheumatoid arthritis-associated interstitial lung disease: a perspective reviewHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateOutcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewPersonalized medicine in rheumatology[Methotrexate toxicity. Myths and facts].Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.Extracellular matrix molecules: potential targets in pharmacotherapy.Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All?Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesisIdentification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.Efficacy of methotrexate in ulcerative colitis: failure or promise.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsRare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymesPhase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.Methotrexate: underused and ignored?Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion.Safety Profiles of Tripterygium wilfordii Hook F: A Systematic Review and Meta-Analysis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatmentThe Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritisEfficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies.Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.Adherence to methotrexate in rheumatoid arthritis: a danish nationwide cohort study.The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry.Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathwayEfficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.A randomized placebo-controlled trial of methotrexate in psoriatic arthritisPatient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis.Folic Acid Supplementation Is Suboptimal in a National Cohort of Older Veterans Receiving Low Dose Oral Methotrexate.EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registryUse of Methotrexate in the Treatment of Inflammatory Bowel Diseases.Short time administration of antirheumatic drugs - methotrexate as a strong inhibitor of osteoblast's proliferation in vitro.
P2860
Q24631295-A199E16C-4AC1-4F72-8D03-F64A06BD13CCQ26739361-1A81BF3C-076C-4BA0-AE70-4506A9B5954FQ26765122-CFA9646E-3027-4993-B710-07F3CE3B99C6Q26775753-B3DBC9EF-8BC9-45A8-9829-926E13DAA2FCQ26777409-EF51A817-AE77-4561-B6C8-01DED64A7C6BQ26852235-C73F78AC-54B0-40F2-8526-C0FCB712BDD0Q26859134-74B8965A-B744-4B38-9A4F-19D69C151E21Q26995202-58C39977-F5B7-4128-B24C-FD0E9EFD7F57Q28077413-34F1044D-9A98-4C15-87F5-B1C296158025Q30318490-19AE0B57-F2CB-4272-BBF1-B6F0069B82D6Q33431836-BA671EAC-AB87-4E26-8A0C-AB6B16C072CEQ33694487-F70ECE7B-9264-46E5-9F80-91DC2E5E968AQ33710680-4515FB23-3292-4909-9BFC-F233A425D3A7Q33845138-162453F7-0CED-4AEF-A78A-5476373A735BQ33921579-3EB96598-0371-4B09-97EE-BB8604A6E17DQ34005379-B0C66DE2-E2CA-47E4-A876-D01244A83702Q34078707-A36A92AB-ABE0-4279-A4C6-4E7110D47C57Q34110066-5C351760-8F1E-41C3-A78D-9DC2596D80E9Q34153004-18D1DF9F-224E-4161-B578-47C7B23CAF68Q34172853-59C2F17C-F980-4F1E-ACD3-BD234A2D2675Q34321255-4E4C0F72-FFA7-4353-B827-EF74C7CACA2AQ34420356-EB5476CA-57D1-4745-930C-DED77EA58C46Q34545406-740031CA-46CB-457E-BB9B-BC3EE8AC8D70Q34559803-8F9BABAC-8434-4CCB-B682-49ED21424FA7Q34563216-E1128328-4675-4029-8815-B301E58D5451Q34607725-9DFA823B-1FDD-4EF4-BF68-AC4BD31FF3DAQ35054330-BA9F76C8-8D6F-4567-AE3E-9DC1ED2B8C68Q35143956-7E4A0921-E37D-4D61-B5C6-4BFE75E45155Q35159896-308CFF79-C185-49A5-A041-E4C327C7DFBAQ35165406-C6F02B4C-F0F3-44B1-83A9-7D891212A0CBQ35622117-CE76BA13-3650-45BB-AEB5-6A4334F17F5DQ35974381-08541E23-5624-46C2-9077-45A6A5A72F74Q36017886-430332D7-06F2-4E2A-8386-DFC8C98F1954Q36036975-7AA97E7A-1E65-4627-87D3-67E78190AA3FQ36096798-161992AC-6457-4986-BFE3-9CDC3837290EQ36145205-75C24210-F41A-4248-B011-CFC497D24D0BQ36225180-E1C4A979-75D8-43D4-B553-B05A9B0CBFA9Q36267465-6347FA8E-304E-470F-9ACC-ABDAD3A927D8Q36372720-1C3641E2-53DC-4EBB-A4FE-D0C29AD12468Q36453573-9F6D61EF-71E8-49B1-A217-2BE7F7351F60
P2860
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term safety of methotrexa ...... ystematic literature research.
@en
Long-term safety of methotrexa ...... ystematic literature research.
@nl
type
label
Long-term safety of methotrexa ...... ystematic literature research.
@en
Long-term safety of methotrexa ...... ystematic literature research.
@nl
prefLabel
Long-term safety of methotrexa ...... ystematic literature research.
@en
Long-term safety of methotrexa ...... ystematic literature research.
@nl
P2860
P31
P356
P1476
Long-term safety of methotrexa ...... ystematic literature research.
@en
P2093
D van der Heijde
P2860
P304
P356
10.1136/ARD.2008.093690
P407
P5008
P577
2008-12-05T00:00:00Z
2009-07-01T00:00:00Z